NanoGuard Technologies, Inc is a Delaware C Corporation located in St. Louis Missouri.  It was founded in 2014 by Nidus Partners, a technology scouting company.   At inception Nidus invested $235,000 as seed funding in NanoGuard.  NanoGuard began building its first plasma generator prototypes in early 2015.  In September 2015 NanoGuard relocated to the Helix Center, an Agricultural Incubator, and installed the multiplate prototype device in its plasma lab.

NanoGuard filed its first patent in October 2015 which covered both microorganisms and mycotoxins in a variety of markets primarily in the food industry.    Subsequently, NanoGuard began negotiating a license for the technology with Bunge Limited.  In August of 2016, NanoGuard signed a license agreement with Bunge Limited.

During 2017 and 2018, NanoGuard focused on perfecting the prototype while continuing to accumulate knowledge on how to treat commodities to reduce mycotoxins and microbes.  In 2018-19, an 8kW pilot device was fabricated from scratch and installed at Bunge’s Creative Research Center in St. Charles.

In May 2019, NanoGuard closed on a $4.75 M Series A Round.  In June 2019, the company filed its second patent protecting the plasma generator device and the electrodes providing further barriers to entry by other competitors.

In 2020 NanoGuard received FDA freedom to operation designation (under FAP) for the antimicrobial use of the technology on food and raw agricultural commodities.  

In November 2021, NanoGuard closed a $3.5 million extension of its series A round with its existing investors to scale the generator for larger commercial applications with increased treatment speed, lower unit production costs, and improved reliability.

Looking ahead, with pilot optimization, NanoGuard is moving from research agreements to commercial agreements, with significant commercial interest by over a dozen potential customers.